On the company’s webpage, PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence, see Commentary, “Understanding skin cancer”.
The strategic shift of sales and marketing continues to prove itself. Despite being a “slow summer quarter”, sales during May – July surpassed sales during any previous quarter.
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.
The strategic shift to focus on digital sales & marketing has been successful, reflected in the sales increase during the latter part of the fiscal year.
